István Horváth

Dr. István Horváth

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2025 in Journal of Nutritional Science
Verified
Journal Article
Open access
PDF file
IHIstván Horváth
István Horváth
GKGyula Kajner
Gyula Kajner
GGGábor Galbács
Gábor Galbács
Dezső CsuporDezső Csupor
Dezső Csupor
Amateur and professional athletes often consume protein supplements to accelerate muscle gain; however, it has been suggested that these products not only are associated with risks when consumed excessively. Several recent reports have indicated that certain products are contaminated with heavy metals. Therefore, in this study, we aimed to investigate protein powders in Hungary for heavy metal contamination. A total of 22 commercially available protein powders (including whey, vegan, and beef based) were purchased on the internet for testing. We analysed the samples using laser-induced breakdown spectroscopy (LIBS) and inductively coupled plasma mass spectrometry (ICP-MS) to assess heavy metal contamination. The products were analysed for the presence of 16 elements (Be, Al, Cr, Mn, Co, Ni, Cu, As, Se, Rb, Cd, Sb, Cs, Ba, Hg, and Pb). The LIBS spectral analysis revealed the characteristics of the protein elements (C, C2, H, N, and O) and alkaline metals (Ca, Na, K, and Mg), which were consistent with the previous results. Neither LIBS nor ICP-MS measurements detected significant heavy metal content in the investigated samples above the limit specified in the regulations. Heavy metal contamination of protein supplements can be a serious health threat. Based on the varied results of the previous studies, it is prudent to include testing for heavy metals as part of the routine and mandatory quality control of these products.

9 October 2026 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PVPéter Vajda
Péter Vajda
GBGábor Bartus
Gábor Bartus
MCMáté Csapó
Máté Csapó
IHIstván Horváth
István Horváth
MVMárton Vajna
Márton Vajna
Romana ZelkoRomana Zelko
Romana Zelko
Background: No licensed ophthalmic 5-fluorouracil (5-FU) product is available in Hungary, and published compounded 5-FU eye drops are alkaline dilutions of the injectable concentrate. We report a formulation development and 28-day storage-stability case study of a pH-adjusted, preservative-free 1% 5-FU eye drop prepared under Council of Europe Resolution CM/Res(2016)1. Methods: Five injectable concentrates were characterised for pH, and one was titrated with 0.1 N hydrochloric acid in a preservative-free ophthalmic vehicle to pH 7.30–7.60. Three 10 mL batches were prepared aseptically and release-tested; drop volume and delivered dose were determined on one batch, which was also followed for 28 days at 15–25 °C and 2–8 °C by inspection, pH, sterility and comparative HPLC-UV assay (single determinations). Results: All concentrates were alkaline (pH 8.95–9.18). The selected formulation reached pH 7.43; individual doses (mean 0.435 mg per drop) were within ±8% of the mean. At 15–25 °C, samples remained clear and sterile, with pH 7.41–7.51 and assay ≥ 97% of initial, without directional trend. At 2–8 °C, precipitate formed from day 7 and the supernatant assay fell to 89.1% by day 28. Conclusions: The preparation remained within specification for 28 days at controlled room temperature but not under refrigeration, consistent with, though not proven to result from, the lower solubility of un-ionised 5-FU. The 28-day period is provisional, not a validated shelf-life; in-use stability, osmolality and viscosity were not established.

25 June 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
DKDénes Kleiner
Dénes Kleiner
IHIstván Horváth
István Horváth
DMDora Matis
Dora Matis
RNRita Nagy
Rita Nagy
Dorottya GergőDorottya Gergő
Dorottya Gergő
Dezső CsuporDezső Csupor
Dezső Csupor
Background/Objectives: Nabiximols, a standardized extract of Cannabis sativa, has been approved as an add-on therapy for patients with moderate to severe spasticity associated with multiple sclerosis (MS). Moreover, current Italian treatment algorithms suggest that cannabis-based therapies may have further relevance in the management of MS. The aim of our systematic review and meta-analysis was to assess the effectiveness of nabiximols in relieving symptoms other than spasticity in adult MS patients. Methods: A systematic search was conducted in Web of Science, MEDLINE (via PubMed), Cochrane CENTRAL and Embase on September 10, 2025. Study selection was performed according to the predefined PROSPERO protocol (CRD42022329952). Data were combined into a common denominator and examined using a random-effects model with meta-regression expressed as mean difference (MD) and a 95% confidence interval (CI). Risk of bias was assessed using the Cochrane risk of bias instrument (RoB2) and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool. Results: Of the 49 eligible articles, 25 were included in the statistical analysis (2949 patients). Significant improvements in spasm quality (MD = −16.87; 95% CI = (−29.75)–(−3.99)), bladder function (MD = −16.38; 95% CI = (−22.18)–(−10.58)), sleep disruption (MD = −15.75; 95% CI = (−22.02)–(−9.49)) and gait function (timed walk MD(s) = −5.31; 95% CI(s) = (−9.88)–(−0.74)) were observed. Time-dependency was not significant. The subject global impression of change (SGIC) improved significantly after the first month (odds ratio (OR) = 1.69; 95% CI = (1.30)–(2.18)). Conclusion: Beyond spasticity, nabiximols may represent a signal of benefit for bladder function, sleep disruption, spasm quality, and gait function in MS, in line with the “spasticity-plus” concept. However, the evidence certainty was low to very low, and these findings should be considered exploratory.